SCHEMBL6948401

SCHEMBL6948401

Cc1ccc(S/C=C/C(=O)O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.67
LMNA P02545 8/20 0.67
NPSR1 Q6W5P4 7/20 0.67
MAPT P10636 5/20 0.67
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
NFKB1 P19838 1/20 0.67
NFKB2 Q00653 1/20 0.67
RELA Q04206 1/20 0.67
HPGD P15428 6/20 0.50
HTT P42858 5/20 0.50
THRB P10828 1/20 0.50
PLIN1 O60240 1/20 0.47
PLIN5 Q00G26 1/20 0.47
ABHD5 Q8WTS1 1/20 0.47
NMT1 P30419 1/20 0.46
PKM P14618 2/20 0.42
ATM Q13315 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NLRP1 Q9C000 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6948405 1.00 ALDH1A1 (0.67) ALDH1A1LMNANPSR1MAPTMEN1
SCHEMBL7456040 0.82 ALDH1A1 (0.60) ALDH1A1LMNANPSR1MAPTMEN1
SCHEMBL600478 0.81 ALDH1A1 (0.68) ALDH1A1LMNANPSR1MAPTMEN1
SCHEMBL9330897 0.81 ALDH1A1 (0.68) ALDH1A1LMNANPSR1MAPTMEN1
SCHEMBL600479 0.81 ALDH1A1 (0.68) ALDH1A1LMNANPSR1MAPTMEN1
SCHEMBL6947763 0.80 MAPT (0.62) ALDH1A1LMNANPSR1MAPTMEN1
SCHEMBL22701981 0.80 ALDH1A1 (0.47) ALDH1A1LMNANPSR1MAPTMEN1
SCHEMBL20697998 0.80 MAPT (0.47) ALDH1A1LMNANPSR1MAPTMEN1
SCHEMBL6944659 0.80 ALDH1A1 (0.47) ALDH1A1LMNANPSR1MAPTMEN1
SCHEMBL6944654 0.80 ALDH1A1 (0.47) ALDH1A1LMNANPSR1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642246-B1 Potent ligands for nicotinic acetylcholine receptors (nAChRs). Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, neuroprotection, schizophrenia, analgesia, Tourette's syndrome, and Parkinson's ASTRAZENECA AB (SE) 2003-11-04 US disclosed
EP-1235826-B1 QUINUCLIDINE ACRYLAMIDES ASTRAZENECA AB (SE) 2003-09-03 EP disclosed
EP-1235826-A1 QUINUCLIDINE ACRYLAMIDES AstraZeneca AB (SE) 2002-09-04 EP disclosed
WO-2001029034-A1 QUINUCLIDINE ACRYLAMIDES ASTRAZENECA AB (SE) 2001-04-26 WO disclosed